Cognetivity Neurosciences (CSE: CGN) this morning announced that it has filed for a key new patent. The filing relates to the use of an artificial intelligence-based system that estimates levels of core biomarkers of neurodegeneration within the brain, which can be utilized to detect, diagnose, and clinically manage disorders such as Alzheimer’s.
The patent reportedly covers what is described as a non-invasive, easy to use device that is capable of estimating fluid biomarker levels, which is effective in managing neurodegenerative disorders such as Alzheimer’s disease and multiple sclerosis. The device is expected to “streamline the process of identifying individuals eligible for specific treatments,” in a manner that is scalable and cost effective, while also being able to monitor disease progression and treatment efficacy.
Following on the heals of the FDA approval of aducanumab, a drug developed by Biogen, the newly developed tech could prove useful for such disorders. Current methodologies for assessing such biomarkers are via PET scans or fluid sampling, both methods of which are time-consuming, expensive and invasive, while not offering any degree of scalability, limiting large-scale use. As a result, timely identification and diagnosis often fails to occur under current practices – something which an AI-based system, such as what has been developed by Cognetivity, could work to solve.
“This will be a vitally important addition to our IP portfolio, and, as the first of its kind for a digital assessment, this demonstrates that Cognetivity is leading the way in developing sophisticated tools that can dramatically improve the patient identification and diagnosis pathway. This paves the way for the fast, timely, disease-specific classification of neurological disorders that is going to be absolutely necessary to deploy on a large scale if we are to combat the dementia crisis.”
Dr Sina Habibi, CEO of Cognetivity
Cognetivity Neurosciences last traded at $0.87 on the CSE.
Sponsored · Altamira Gold Corp.
FULL DISCLOSURE: Cognetivity Neurosciences Ltd is a client of Canacom Group, the parent company of The Deep Dive. The author has been compensated to cover Cognetivity Neurosciences Ltd on The Deep Dive, with The Deep Dive having full editorial control. Not a recommendation to buy or sell. Always do additional research and consult a professional before purchasing a security.
